Principles of Pharmacotherapy of Seizures and Status Epilepticus

Caroline Der-Nigoghossian; Eljim P. Tesoro; Micheal Strein; Gretchen M. Brophy

doi:10.1055/s-0040-1718721

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2020; 40(06): 681-695
DOI: 10.1055/s-0040-1718721

Review Article

Principles of Pharmacotherapy of Seizures and Status Epilepticus

Caroline Der-Nigoghossian

¹Department of Pharmacy, Neurosciences Intensive Care Unit, New York-Presbyterian Hospital/Columbia University Irving Medical Center, New York, New York

,

Eljim P. Tesoro

²Department of Pharmacy Practice (MC 886), College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois

,

Micheal Strein

³Pharmacotherapy and Outcomes Science and Neurosurgery, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia

,

Gretchen M. Brophy

³Pharmacotherapy and Outcomes Science and Neurosurgery, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, Virginia

› Institutsangaben

Abstract

Status epilepticus is a neurological emergency with an outcome that is highly associated with the initial pharmacotherapy management that must be administered in a timely fashion. Beyond first-line therapy of status epilepticus, treatment is not guided by robust evidence. Optimal pharmacotherapy selection for individual patients is essential in the management of seizures and status epilepticus with careful evaluation of pharmacokinetic and pharmacodynamic factors. With the addition of newer antiseizure agents to the market, understanding their role in the management of status epilepticus is critical. Etiology-guided therapy should be considered in certain patients with drug-induced seizures, alcohol withdrawal, or autoimmune encephalitis. Some patient populations warrant special consideration, such as pediatric, pregnant, elderly, and the critically ill. Seizure prophylaxis is indicated in select patients with acute neurological injury and should be limited to the acute postinjury period.

Keywords

status epilepticus - seizure - treatment - antiseizure drugs

Volltext

Referenzen

References
1 Neligan A, Noyce AJ, Gosavi TD, Shorvon SD, Köhler S, Walker MC. Change in mortality of generalized convulsive status epilepticus in high-income countries over time: a systematic review and meta-analysis. JAMA Neurol 2019; 76 (08) 897-905
2 Brophy GM, Bell R, Claassen J. Neurocritical Care Society Status Epilepticus Guideline Writing Committee. et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17 (01) 3-23
3 Glauser T, Shinnar S, Gloss D. et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr 2016; 16 (01) 48-61
4 Kellinghaus C, Rossetti AO, Trinka E. et al. Factors predicting cessation of status epilepticus in clinical practice: data from a prospective observational registry (SENSE). Ann Neurol 2019; 85 (03) 421-432
5 Sathe AG, Tillman H, Coles LD. et al. Underdosing of benzodiazepines in patients with status epilepticus enrolled in Established Status Epilepticus Treatment Trial. Acad Emerg Med 2019; 26 (08) 940-943
6 Treiman DM, Meyers PD, Walton NY. Veterans Affairs Status Epilepticus Cooperative Study Group. et al. A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 1998; 339 (12) 792-798
7 Alldredge BK, Gelb AM, Isaacs SM. et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med 2001; 345 (09) 631-637
8 Silbergleit R, Durkalski V, Lowenstein D. NETT Investigators. et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012; 366 (07) 591-600
9 Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002; 43 (02) 146-153
10 Rossetti AO, Milligan TA, Vulliémoz S, Michaelides C, Bertschi M, Lee JW. A randomized trial for the treatment of refractory status epilepticus. Neurocrit Care 2011; 14 (01) 4-10
11 Boulieu R, Lehmann B, Salord F, Fisher C, Morlet D. Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients. Eur J Drug Metab Pharmacokinet 1998; 23 (02) 255-258
12 Backman JT, Olkkola KT, Ojala M, Laaksovirta H, Neuvonen PJ. Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin. Epilepsia 1996; 37 (03) 253-257
13 Fodale V, La Monaca E. Propofol infusion syndrome: an overview of a perplexing disease. Drug Saf 2008; 31 (04) 293-303
14 Krajčová A, Waldauf P, Anděl M, Duška F. Propofol infusion syndrome: a structured review of experimental studies and 153 published case reports. Crit Care 2015; 19: 398
15 Kapetanović IM, Kupferberg HJ, Porter RJ, Theodore W, Schulman E, Penry JK. Mechanism of valproate-phenobarbital interaction in epileptic patients. Clin Pharmacol Ther 1981; 29 (04) 480-486
16 Pokrajac M, Miljković B, Varagić VM, Lević Z. Pharmacokinetic interaction between valproic acid and phenobarbital. Biopharm Drug Dispos 1993; 14 (01) 81-86
17 Ehrnebo M. Pharmacokinetics and distribution properties of pentobarbital in humans following oral and intravenous administration. J Pharm Sci 1974; 63 (07) 1114-1118
18 McKindley DS, Hanes S, Boucher BA. Hepatic drug metabolism in critical illness. Pharmacotherapy 1998; 18 (04) 759-778
19 Bayliff CD, Schwartz ML, Hardy BG. Pharmacokinetics of high-dose pentobarbital in severe head trauma. Clin Pharmacol Ther 1985; 38 (04) 457-461
20 Heinemeyer G, Roots I, Dennhardt R. Monitoring of pentobarbital plasma levels in critical care patients suffering from increased intracranial pressure. Ther Drug Monit 1986; 8 (02) 145-150
21 Wermeling DP, Blouin RA, Porter WH, Rapp RP, Tibbs PA. Pentobarbital pharmacokinetics in patients with severe head injury. Drug Intell Clin Pharm 1987; 21 (05) 459-463
22 Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134 (Pt 10): 2802-2818
23 Naylor DE, Liu H, Niquet J, Wasterlain CG. Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus. Neurobiol Dis 2013; 54: 225-238
24 Mazarati AM, Wasterlain CG. N-methyl-D-asparate receptor antagonists abolish the maintenance phase of self-sustaining status epilepticus in rat. Neurosci Lett 1999; 265 (03) 187-190
25 Rosati A, L'Erario M, Ilvento L. et al. Efficacy and safety of ketamine in refractory status epilepticus in children. Neurology 2012; 79 (24) 2355-2358
26 Gaspard N, Foreman B, Judd LM. et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 2013; 54 (08) 1498-1503
27 Kramer AH. Early ketamine to treat refractory status epilepticus. Neurocrit Care 2012; 16 (02) 299-305
28 Mion G, Villevieille T. Ketamine pharmacology: an update (pharmacodynamics and molecular aspects, recent findings). CNS Neurosci Ther 2013; 19 (06) 370-380
29 Yan J, Jiang H. Dual effects of ketamine: neurotoxicity versus neuroprotection in anesthesia for the developing brain. J Neurosurg Anesthesiol 2014; 26 (02) 155-160
30 Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: mechanism and prevention. Science 1991; 254 (5037): 1515-1518
31 Zeiler FA, Teitelbaum J, West M, Gillman LM. The ketamine effect on ICP in traumatic brain injury. Neurocrit Care 2014; 21 (01) 163-173
32 Green SM, Roback MG, Kennedy RM, Krauss B. Clinical practice guideline for emergency department ketamine dissociative sedation: 2011 update. Ann Emerg Med 2011; 57 (05) 449-461
33 Perouansky M, Baranov D, Salman M, Yaari Y. Effects of halothane on glutamate receptor-mediated excitatory postsynaptic currents. A patch-clamp study in adult mouse hippocampal slices. Anesthesiology 1995; 83 (01) 109-119
34 Campagna JA, Miller KW, Forman SA. Mechanisms of actions of inhaled anesthetics. N Engl J Med 2003; 348 (21) 2110-2124
35 Olsen RW. The molecular mechanism of action of general anesthetics: structural aspects of interactions with GABA(A) receptors. Toxicol Lett 1998; 100–101: 193-201
36 Harrison NL, Kugler JL, Jones MV, Greenblatt EP, Pritchett DB. Positive modulation of human gamma-aminobutyric acid type A and glycine receptors by the inhalation anesthetic isoflurane. Mol Pharmacol 1993; 44 (03) 628-632
37 Iijima T, Nakamura Z, Iwao Y, Sankawa H. The epileptogenic properties of the volatile anesthetics sevoflurane and isoflurane in patients with epilepsy. Anesth Analg 2000; 91 (04) 989-995
38 Mirsattari SM, Sharpe MD, Young GB. Treatment of refractory status epilepticus with inhalational anesthetic agents isoflurane and desflurane. Arch Neurol 2004; 61 (08) 1254-1259
39 Riviello Jr JJ, Claassen J, LaRoche SM. Neurocritical Care Society Status Epilepticus Guideline Writing Committee. et al. Treatment of status epilepticus: an international survey of experts. Neurocrit Care 2013; 18 (02) 193-200
40 Navarro V, Dagron C, Elie C. SAMUKeppra investigators. et al. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. Lancet Neurol 2016; 15 (01) 47-55
41 Kapur J, Elm J, Chamberlain JM. NETT and PECARN Investigators. et al. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med 2019; 381 (22) 2103-2113
42 Husain AM, Lee JW, Kolls BJ. Critical Care EEG Monitoring Research Consortium. et al. Randomized trial of lacosamide versus fosphenytoin for nonconvulsive seizures. Ann Neurol 2018; 83 (06) 1174-1185
43 Strzelczyk A, Zöllner JP, Willems LM. et al. Lacosamide in status epilepticus: Systematic review of current evidence. Epilepsia 2017; 58 (06) 933-950
44 Legros B, Depondt C, Levy-Nogueira M. et al. Intravenous lacosamide in refractory seizure clusters and status epilepticus: comparison of 200 and 400 mg loading doses. Neurocrit Care 2014; 20 (03) 484-488
45 Kalss G, Rohracher A, Leitinger M. et al. Intravenous brivaracetam in status epilepticus: a retrospective single-center study. Epilepsia 2018; 59 (Suppl. 02) 228-233
46 Strzelczyk A, Steinig I, Willems LM. et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav 2017; 70 (Pt A): 177-181
47 Mahmoud SH, Rans C. Systematic review of clobazam use in patients with status epilepticus. Epilepsia Open 2018; 3 (03) 323-330
48 Hocker S. Perampanel for refractory status epilepticus… another tool in the armamentarium. Neurocrit Care 2019; 31 (01) 30-31
49 Redecker J, Wittstock M, Benecke R, Rösche J. Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav 2015; 45: 176-179
50 Rohracher A, Kalss G, Neuray C. et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: a single-center audit of 30 patients. Epilepsia 2018; 59 (Suppl. 02) 234-242
51 Legriel S, Oddo M, Brophy GM. What's new in refractory status epilepticus?. Intensive Care Med 2017; 43 (04) 543-546
52 Davidson KE, Newell J, Alsherbini K, Krushinski J, Jones GM. Safety and efficiency of intravenous push lacosamide administration. Neurocrit Care 2018; 29 (03) 491-495
53 Morgan O, Medenwald B. Safety and tolerability of rapid administration undiluted levetiracetam. Neurocrit Care 2019; 32 (01) 131-134
54 UCB, Inc.. Briviact (brivaracetam) [package insert]. U.S. Food and Drug Administration website. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205836Orig1s000,205837Orig1s000,205838Orig1s000lbl.pdf. Revised February 2016. Accessed September 3, 2019
55 Lamson MJ, Sitki-Green D, Wannarka GL, Mesa M, Andrews P, Pellock J. Pharmacokinetics of diazepam administered intramuscularly by autoinjector versus rectal gel in healthy subjects: a phase I, randomized, open-label, single-dose, crossover, single-centre study. Clin Drug Investig 2011; 31 (08) 585-597
56 Wermeling DP, Miller JL, Archer SM, Manaligod JM, Rudy AC. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmacol 2001; 41 (11) 1225-1231
57 7.4 Intramuscular Injections – Clinical Procedures for Safer Patient Care. Available at: https://opentextbc.ca/clinicalskills/chapter/6-8-iv-push-medications-and-saline-lock-flush/. Accessed August 13, 2019
58 Boucher BA, Feler CA, Dean JC. et al. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients. Pharmacotherapy 1996; 16 (04) 638-645
59 Ramsay RE, Wilder BJ, Uthman BM. et al. Intramuscular fosphenytoin (Cerebyx) in patients requiring a loading dose of phenytoin. Epilepsy Res 1997; 28 (03) 181-187
60 Scheepers M, Scheepers B, Clarke M, Comish S, Ibitoye M. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy?. Seizure 2000; 9 (06) 417-422
61 Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH. Mechanism of intranasal drug delivery directly to the brain. Life Sci 2018; 195: 44-52
62 Türker S, Onur E, Ozer Y. Nasal route and drug delivery systems. Pharm World Sci 2004; 26 (03) 137-142
63 Wermeling DP, Record KA, Archer SM, Rudy AC. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. Epilepsy Res 2009; 83 (2-3): 124-132
64 Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav 2004; 5 (02) 253-255
65 Schrier L, Zuiker R, Merkus FWHM. et al. Pharmacokinetics and pharmacodynamics of a new highly concentrated intranasal midazolam formulation for conscious sedation. Br J Clin Pharmacol 2017; 83 (04) 721-731
66 Deng-Bryant Y, Readnower R, Leung LY, Tortella F, Shear D. Methods of drug delivery in neurotrauma. Methods Mol Biol 2016; 1462: 89-100
67 de Boer AG, Moolenaar F, de Leede LGJ, Breimer DD. Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokinet 1982; 7 (04) 285-311
68 Anderson GD, Saneto RP. Current oral and non-oral routes of antiepileptic drug delivery. Adv Drug Deliv Rev 2012; 64 (10) 911-918
69 Moolenaar F, Koning B, Huizinga T. Biopharmaceutics of rectal administration of drugs in man 7. Absorption rate and bioavailability of phenobarbital and its sodium salt from rectal dosage forms. Int J Pharm 1979; 4 (02) 99-109
70 Dreifuss FE, Rosman NP, Cloyd JC. et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med 1998; 338 (26) 1869-1875
71 Scott RC, Besag FM, Boyd SG, Berry D, Neville BG. Buccal absorption of midazolam: pharmacokinetics and EEG pharmacodynamics. Epilepsia 1998; 39 (03) 290-294
72 Mpimbaza A, Ndeezi G, Staedke S, Rosenthal PJ, Byarugaba J. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics 2008; 121 (01) e58-e64
73 Scott RC, Besag FM, Neville BG. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999; 353 (9153): 623-626
74 Lee D, Gladwell D, Batty AJ, Brereton N, Tate E. The cost effectiveness of licensed oromucosal midazolam (Buccolam(®)) for the treatment of children experiencing acute epileptic seizures: an approach when trial evidence is limited. Paediatr Drugs 2013; 15 (02) 151-162
75 Molin R, Hallas P, Brabrand M, Schmidt TA. Preferred anatomic site for intraosseous infusion in Danish emergency departments. Scand J Trauma Resusc Emerg Med 2010; 18 (Suppl. 01) 26
76 Paxton JH, Knuth TE, Klausner HA. Proximal humerus intraosseous infusion: a preferred emergency venous access. J Trauma 2009; 67 (03) 606-611
77 Anson JA. Vascular access in resuscitation: is there a role for the intraosseous route?. Anesthesiology 2014; 120 (04) 1015-1031
78 Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007; 27 (10) 1425-1439
79 Lheureux PER, Penaloza A, Zahir S, Gris M. Science review: carnitine in the treatment of valproic acid-induced toxicity - what is the evidence?. Crit Care 2005; 9 (05) 431-440
80 Mock CM, Schwetschenau KH. Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy. Am J Health Syst Pharm 2012; 69 (01) 35-39
81 Brodie MJ, Mintzer S, Pack AM, Gidal BE, Vecht CJ, Schmidt D. Enzyme induction with antiepileptic drugs: cause for concern?. Epilepsia 2013; 54 (01) 11-27
82 Mancl EE, Gidal BE. The effect of carbapenem antibiotics on plasma concentrations of valproic acid. Ann Pharmacother 2009; 43 (12) 2082-2087
83 Tantikittichaikul S, Johnson J, Laengvejkal P, DeToledo J. Topiramate-induced hyperammonemic encephalopathy in a patient with mental retardation: a case report and review of the literature. Epilepsy Behav Case Rep 2015; 4: 84-85
84 Au Yeung SC, Ensom MH. Phenytoin and enteral feedings: does evidence support an interaction?. Ann Pharmacother 2000; 34 (7–8): 896-905
85 van der Louw EJTM, Desadien R, Vehmeijer FOL, van der Sijs H, Catsman-Berrevoets CE, Neuteboom RF. Concomitant lamotrigine use is associated with decreased efficacy of the ketogenic diet in childhood refractory epilepsy. Seizure 2015; 32: 75-77
86 Patsalos PN, Spencer EP, Berry DJ. Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update. Ther Drug Monit 2018; 40 (05) 526-548
87 Javadi S-S, Mahjub R, Taher A, Mohammadi Y, Mehrpooya M. Correlation between measured and calculated free phenytoin serum concentration in neurointensive care patients with hypoalbuminemia. Clin Pharmacol 2018; 10: 183-190
88 Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol 2013; 149 (09) 1025-1032
89 Li X, Yu K, Mei S. et al. HLA-B*1502 increases the risk of phenytoin or lamotrigine induced Stevens-Johnson Syndrome/toxic epidermal necrolysis: evidence from a meta-analysis of nine case-control studies. Drug Res (Stuttg) 2015; 65 (02) 107-111
90 Deng Y, Li S, Zhang L, Jin H, Zou X. Association between HLA alleles and lamotrigine-induced cutaneous adverse drug reactions in Asian populations: a meta-analysis. Seizure 2018; 60: 163-171
91 Abend NS, Loddenkemper T. Pediatric status epilepticus management. Curr Opin Pediatr 2014; 26 (06) 668-674
92 Hemphill S, McMenamin L, Bellamy MC, Hopkins PM. Propofol infusion syndrome: a structured literature review and analysis of published case reports. Br J Anaesth 2019; 122 (04) 448-459
93 Rajiv KR, Radhakrishnan A. Status epilepticus in pregnancy: etiology, management, and clinical outcomes. Epilepsy Behav 2017; 76: 114-119
94 Tomson T, Landmark CJ, Battino D. Antiepileptic drug treatment in pregnancy: changes in drug disposition and their clinical implications. Epilepsia 2013; 54 (03) 405-414
95 Moussa HN, Ontiveros AE, Haidar ZA, Sibai BM. Safety of anticonvulsant agents in pregnancy. Expert Opin Drug Saf 2015; 14 (10) 1609-1620
96 Leppik IE. Status epilepticus in the elderly. Epilepsia 2018; 59 (Suppl. 02) 140-143
97 Motika PV, Spencer DC. Treatment of epilepsy in the elderly. Curr Neurol Neurosci Rep 2016; 16 (11) 96
98 Lezaic N, Gore G, Josephson CB, Wiebe S, Jetté N, Keezer MR. The medical treatment of epilepsy in the elderly: a systematic review and meta-analysis. Epilepsia 2019; 60 (07) 1325-1340
99 Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J. Introduction to drug pharmacokinetics in the critically ill patient. Chest 2012; 141 (05) 1327-1336
100 Smetana KS, Cook AM, Bastin MLT, Oyler DR. Antiepileptic dosing for critically ill adult patients receiving renal replacement therapy. J Crit Care 2016; 36: 116-124
101 May CC, Arora S, Parli SE, Fraser JF, Bastin MT, Cook AM. Augmented renal clearance in patients with subarachnoid hemorrhage. Neurocrit Care 2015; 23 (03) 374-379
102 Udy AA, Roberts JA, Boots RJ, Paterson DL, Lipman J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49 (01) 1-16
103 Cook AM, Hatton-Kolpek J. Augmented renal clearance. Pharmacotherapy 2019; 39 (03) 346-354
104 Šunjić KM, Webb AC, Šunjić I, Palà Creus M, Folse SL. Pharmacokinetic and other considerations for drug therapy during targeted temperature management. Crit Care Med 2015; 43 (10) 2228-2238
105 Hirsch LJ, Gaspard N, van Baalen A. et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 2018; 59 (04) 739-744
106 Gaspard N, Foreman BP, Alvarez V. Critical Care EEG Monitoring Research Consortium (CCEMRC). et al. New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology 2015; 85 (18) 1604-1613
107 Gaspard N. Autoimmune epilepsy. Continuum (Minneap Minn) 2016; 22 (1 Epilepsy): 227-245
108 Bayrlee A, Ganeshalingam N, Kurczewski L, Brophy GM. Treatment of super-refractory status epilepticus. Curr Neurol Neurosci Rep 2015; 15 (10) 66
109 Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med 1990; 323 (08) 497-502
110 Temkin NR, Dikmen SS, Anderson GD. et al. Valproate therapy for prevention of posttraumatic seizures: a randomized trial. J Neurosurg 1999; 91 (04) 593-600
111 Carney N, Totten AM, O'Reilly C. et al. Guidelines for the management of severe traumatic brain injury, fourth edition. Neurosurgery 2017; 80 (01) 6-15
112 Wat R, Mammi M, Paredes J. et al. The effectiveness of antiepileptic medications as prophylaxis of early seizure in patients with traumatic brain injury compared with placebo or no treatment: a systematic review and meta-analysis. World Neurosurg 2019; 122: 433-440
113 Inaba K, Menaker J, Branco BC. et al. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. J Trauma Acute Care Surg 2013; 74 (03) 766-771 , discussion 771–773
114 Chumnanvej S, Dunn IF, Kim DH. Three-day phenytoin prophylaxis is adequate after subarachnoid hemorrhage. Neurosurgery 2007; 60 (01) 99-102 , discussion 102–103
115 Human T, Diringer MN, Allen M. et al. A randomized trial of brief versus extended seizure prophylaxis after aneurysmal subarachnoid hemorrhage. Neurocrit Care 2018; 28 (02) 169-174
116 Rosengart AJ, Huo JD, Tolentino J. et al. Outcome in patients with subarachnoid hemorrhage treated with antiepileptic drugs. J Neurosurg 2007; 107 (02) 253-260
117 Naidech AM, Kreiter KT, Janjua N. et al. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. Stroke 2005; 36 (03) 583-587
118 Tartara A, Galimberti CA, Manni R. et al. Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients. Br J Clin Pharmacol 1991; 32 (03) 335-340
119 Connolly Jr ES, Rabinstein AA, Carhuapoma JR. American Heart Association Stroke Council, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Clinical Cardiology. et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/american Stroke Association. Stroke 2012; 43 (06) 1711-1737
120 Diringer MN, Bleck TP, Claude Hemphill III J. Neurocritical Care Society. et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the Neurocritical Care Society's Multidisciplinary Consensus Conference. Neurocrit Care 2011; 15 (02) 211-240
121 Hemphill III JC, Greenberg SM, Anderson CS. American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology. et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2015; 46 (07) 2032-2060
122 Mackey J, Blatsioris AD, Moser EAS. et al. Prophylactic anticonvulsants in intracerebral hemorrhage. Neurocrit Care 2017; 27 (02) 220-228
123 Naidech AM, Garg RK, Liebling S. et al. Anticonvulsant use and outcomes after intracerebral hemorrhage. Stroke 2009; 40 (12) 3810-3815
124 Messé SR, Sansing LH, Cucchiara BL, Herman ST, Lyden PD, Kasner SE. CHANT investigators. Prophylactic antiepileptic drug use is associated with poor outcome following ICH. Neurocrit Care 2009; 11 (01) 38-44
125 Ogilvy CS, Stieg PE, Awad I. Stroke Council, American Stroke Association. et al. Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the Stroke Council, American Stroke Association. Circulation 2001; 103 (21) 2644-2657
126 Pulman J, Greenhalgh J, Marson AG. Antiepileptic drugs as prophylaxis for post-craniotomy seizures. Cochrane Database Syst Rev 2013; (02) CD007286
127 Powers WJ, Rabinstein AA, Ackerson T. American Heart Association Stroke Council. et al. 2018 Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018; 49 (03) e46-e110
128 Chen CC, Rennert RC, Olson JJ. Congress of Neurological Surgeons systematic review and evidence-based guidelines on the role of prophylactic anticonvulsants in the treatment of adults with metastatic brain tumors. Neurosurgery 2019; 84 (03) E195-E197
129 Mikkelsen T, Paleologos NA, Robinson PD. et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010; 96 (01) 97-102
130 Komotar RJ, Raper DMS, Starke RM, Iorgulescu JB, Gutin PH. Prophylactic antiepileptic drug therapy in patients undergoing supratentorial meningioma resection: a systematic analysis of efficacy. J Neurosurg 2011; 115 (03) 483-490
131 Tremont-Lukats IW, Ratilal BO, Armstrong T, Gilbert MR. Antiepileptic drugs for preventing seizures in people with brain tumors. Cochrane Database Syst Rev 2008; (02) CD004424
132 Pandey S, Rathore C, Michael BD. Antiepileptic drugs for the primary and secondary prevention of seizures in viral encephalitis. Cochrane Database Syst Rev 2016; (05) CD010247
133 Lipari RN, Williams MR, Copello EAP, Pemberton MR. Risk and protective factors and estimates of substance use initiation: results from the 2015 National Survey on Drug Use and Health. In: CBHSQ Data Review. Rockville, MD: Substance Abuse and Mental Health Services Administration (US); 2012
134 Banger M, Philipp M, Herth T, Hebenstreit M, Aldenhoff J. Development of a rating scale for quantitative measurement of the alcohol withdrawal syndrome. Eur Arch Psychiatry Clin Neurosci 1992; 241 (04) 241-246
135 Wetterling T, Kanitz RD, Besters B. et al. A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale). Alcohol Alcohol 1997; 32 (06) 753-760
136 Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). Br J Addict 1989; 84 (11) 1353-1357
137 Lyon JE, Khan RA, Gessert CE, Larson PM, Renier CM. Treating alcohol withdrawal with oral baclofen: a randomized, double-blind, placebo-controlled trial. J Hosp Med 2011; 6 (08) 469-474
138 Mueller SW, Preslaski CR, Kiser TH. et al. A randomized, double-blind, placebo-controlled dose range study of dexmedetomidine as adjunctive therapy for alcohol withdrawal. Crit Care Med 2014; 42 (05) 1131-1139
139 Wong A, Benedict NJ, Armahizer MJ, Kane-Gill SL. Evaluation of adjunctive ketamine to benzodiazepines for management of alcohol withdrawal syndrome. Ann Pharmacother 2015; 49 (01) 14-19
140 Hendey GW, Dery RA, Barnes RL, Snowden B, Mentler P. A prospective, randomized, trial of phenobarbital versus benzodiazepines for acute alcohol withdrawal. Am J Emerg Med 2011; 29 (04) 382-385
141 Rosenson J, Clements C, Simon B. et al. Phenobarbital for acute alcohol withdrawal: a prospective randomized double-blind placebo-controlled study. J Emerg Med 2013; 44 (03) 592.e2-598.e2
142 Gipson G, Tran K, Hoang C, Treggiari M. Comparison of enteral ethanol and benzodiazepines for alcohol withdrawal in neurocritical care patients. J Clin Neurosci 2016; 31: 88-91
143 Coffey RJ, Edgar TS, Francisco GE. et al. Abrupt withdrawal from intrathecal baclofen: recognition and management of a potentially life-threatening syndrome. Arch Phys Med Rehabil 2002; 83 (06) 735-741
144 Douglas AF, Weiner HL, Schwartz DR. Prolonged intrathecal baclofen withdrawal syndrome. Case report and discussion of current therapeutic management. J Neurosurg 2005; 102 (06) 1133-1136
145 Salazar ML, Eiland LS. Intrathecal baclofen withdrawal resembling serotonin syndrome in an adolescent boy with cerebral palsy. Pediatr Emerg Care 2008; 24 (10) 691-693
146 Ackland GL, Fox R. Low-dose propofol infusion for controlling acute hyperspasticity after withdrawal of intrathecal baclofen therapy. Anesthesiology 2005; 103 (03) 663-665
147 Saveika JA, Shelton JE. Cyproheptadine for pediatric intrathecal baclofen withdrawal: a case report. Am J Phys Med Rehabil 2007; 86 (12) 994-997
148 Reeves RK, Stolp-Smith KA, Christopherson MW. Hyperthermia, rhabdomyolysis, and disseminated intravascular coagulation associated with baclofen pump catheter failure. Arch Phys Med Rehabil 1998; 79 (03) 353-356
149 Bellinger A, Siriwetchadarak R, Rosenquist R, Greenlee JDW. Prevention of intrathecal baclofen withdrawal syndrome: successful use of a temporary intrathecal catheter. Reg Anesth Pain Med 2009; 34 (06) 600-602
150 Medtronic. Baclofen Pump Alarms | ITB Therapy | Medtronic. Available at: https://www.medtronic.com/uk-en/patients/treatments-therapies/drug-pump-severe-spasticity/living-with/safety-pump-alarms.html. Accessed May 13, 2020
151 Dham BS, Hunter K, Rincon F. The epidemiology of status epilepticus in the United States. Neurocrit Care 2014; 20 (03) 476-483
152 Sutter R, Rüegg S, Tschudin-Sutter S. Seizures as adverse events of antibiotic drugs: A systematic review. Neurology 2015; 85 (15) 1332-1341
153 Naeije G, Lorent S, Vincent J-L, Legros B. Continuous epileptiform discharges in patients treated with cefepime or meropenem. Arch Neurol 2011; 68 (10) 1303-1307
154 Payne LE, Gagnon DJ, Riker RR. et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care 2017; 21 (01) 276
155 Cannon JP, Lee TA, Clark NM, Setlak P, Grim SA. The risk of seizures among the carbapenems: a meta-analysis. J Antimicrob Chemother 2014; 69 (08) 2043-2055
156 Song T, Rao Z, Tan Q. et al. Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation: report of 2 cases and literature review. Medicine (Baltimore) 2016; 95 (14) e3173
157 Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002; 25 (02) 91-110
158 Lappin JM, Sara GE. Psychostimulant use and the brain. Addiction 2019; 114 (11) 2065-2077
159 Lexi-Drugs, Lexicomp, Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: http://Online.Lexi.Com. Accessed May 13, 2020
160 Venkatesan A. Immune-mediated encephalitis for the infectious disease specialist. Curr Opin Infect Dis 2019; 32 (03) 251-258
161 Sculier C, Gaspard N. New onset refractory status epilepticus (NORSE). Seizure 2019; 68: 72-78
162 Lee W-J, Lee S-T, Moon J. et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics 2016; 13 (04) 824-832
163 Loscher W, Schmidt D. Epilepsy: perampanel-new promise for refractory epilepsy?. Nat Rev Neurol 2012; 8: 661-662